EcoDrugPlus

Exportin 1

Ensembl ID : ENSMLUG00000010670
Gene Symbol: XPO1
4 Cross references
304 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSMLUG00000005508
Gene Symbol: FDFT1
2 Cross references
215 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSMLUG00000002921
Gene Symbol: FNTA
2 Cross references
216 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSMLUG00000004312
Gene Symbol: FNTB
2 Cross references
210 Possible Orthologues:

Fatty Acid Amide Hydrolase

Ensembl ID : ENSMLUG00000005452
Gene Symbol: FAAH
2 Cross references
131 Possible Orthologues:

Fibroblast Activation Protein Alpha

Ensembl ID : ENSMLUG00000009468
Gene Symbol: FAP
2 Cross references
127 Possible Orthologues:

Fibroblast Growth Factor 2

Ensembl ID : ENSMLUG00000023354
Gene Symbol: FGF2
1 Cross references
117 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSMLUG00000001759
Gene Symbol: FGFR1
2 Cross references
289 Possible Orthologues:

Fibroblast Growth Factor Receptor 4

Ensembl ID : ENSMLUG00000005601
Gene Symbol: FGFR4
2 Cross references
123 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSMLUG00000004358
Gene Symbol: FLT1
2 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSMLUG00000002582
Gene Symbol: FLT3
2 Cross references
133 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSMLUG00000009835
Gene Symbol: FLT4
4 Cross references
195 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).